Sofosbuvir drug interactions
Sovaldi (Sofosbuvir) is a hepatitis C virus (HCV) inhibitor suggested and specified for the treatment of chronic hepatitis C infection. It is a component of a complex antiviral course of treatment.
The following details should be taken into account when the treatment with Sovaldi has a cause to begin:
The single therapy with Sovaldi is not approved for treatment of chronic hepatitis C.
Treatment course and length of therapy are expected to depend on viral genotype and patient group.
The reaction to the treatment may differ with accordance to a variety of factors.
Sovaldi was approved in Europe in the beginning of 2014 for treatment of adult patients with all genotypes of chronic hepatitis C (CHC).
Actually, Sofosbuvir represents the first interferon-free hepatitis C treatment choice. It can significantly decrease the treatment when added to pegylated interferon and ribavirin.
Successful therapy diminishes the hazards of long-term health circumstances of hepatitis C including liver cancer or requirement for a liver transplant.
Prior to the initiation of the treatment with Sofosbuvir it is absolutely necessary to estimate the risks and benefits for each patient.
Hepatitis treatment involves usage of many different medicines which can interact if used together or administered improperly.
The possibility of drug interactions with Sofosbuvir should be assessed before co-administration.
Such drugs as rifampin or St. John's wort may decrease Sofosbuvir concentration in blood. This can reduce the therapeutic effect of the medicine. The use of the mentioned above drugs is not recommended with Sovaldi.
Various combinations of medicines with Sovaldi were tested during clinical trials. Co-administration of some drugs with Sovaldi is possible and safe, still there are some drugs which should be avoided with Sofosbuvir. Interaction studies were conducted in healthy people. So, the administration of Sovaldi with other medicines in patients suffering from hepatitis and other conditions may differ from the results obtained from the studies. Regular control and monitoring is necessary for patients having liver or kidney malfunction and other serious health conditions.
According to the studies Sofosbuvir can be safely co-administered with the following medicines:cyclosporine, darunavir/ritonavir, efavirenz, emtricitabine, methadone, or rilpivirine.
Sovaldi is used in combination with Ribavirin and Peginterferon Alfa medicines.
Peginterferon alfa is given in a form of injection. It is given under the skin once in a week. Ribavirin dose is adjusted by a doctor.
If you have been prescribed to use Sovaldi in combination with other medicines, make sure you fully perceive how to apply the medicine. Do not disregard any specifications of use.